-
Professor Dingwei Ye: A “Precision Breakthrough” in Prostate Cancer Prevention and Treatment in China | 2025 Pujiang Prostate Cancer Congress
As the tides of the Pujiang River surge forward, so too does China’s momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese…
-
Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress
The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,”…
-
2025 ICML | Professor Donglu Zhao: China’s Perspective on DLBCL Treatment Innovation — Novel Strategies, Practical Exploration, and Global Implication
A major highlight of the conference was the special academic session co-organized by the Union for China Lymphoma Investigators (UCLI) and ICML. In this session, Professor Donglu Zhao from the…
-
2025 ICML | Professor Jianyong Li: Dual LYN/BTK Inhibitor DZD8586 Breaks Through Resistance Barriers in CLL/SLL
Hematology Frontier: Recent data show that DZD8586 achieved an objective response rate (ORR) of 84.2% in R/R CLL/SLL patients previously treated with covalent/non-covalent BTK inhibitors or BTK degraders. What are…
-
EHA Spotlight | Profs. Jiang, Chen & Cao: AI-Powered Precision GVHD Prevention with daGOAT
Oncology Frontier – Hematology Frontier: Congratulations on having your study selected for an oral presentation at the congress. The daGOAT model is a key highlight of your research. Could you…
-
Exp Hematol Oncol | Prof. Xiaoxia Hu’s Team Uncovers EBV Risks in the Letermovir Era
Background EBV reactivation occurs in 19.6%–65.0% of allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients and is closely related to post-transplant lymphoproliferative disease (PTLD). Letermovir is effective in reducing CMV reactivation,…
-
AJH Major Publication | Chinese Team First to Discover Prognostic Value of NK Cell Chimerism in Post-Transplant MRD-Negative Patients
Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a potentially curative option for various hematologic malignancies. However, disease relapse remains the primary cause of treatment failure. Donor-derived immune cells play…
-
2025 ICML | Prof. Lu-Gui Qiu on Igemetostat’s Broad Efficacy in R/R NHL and Future Strategies
At the conference, Professor Lu-Gui Qiu from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the results of a Phase I/II clinical trial investigating…
Connecting Medical Expertise through Media